A Phase 2 interventional study of XW003 injection and semaglutide injection in Obesity and Weight Management, sponsored by Hangzhou Sciwind Biosciences Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Hangzhou Sciwind Biosciences Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. — 7 open to participants now, 8 under way, 4 of them phase 3. Obesity · Hangzhou Sciwind Biosciences Co., Ltd..
Among the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., this one is the 5th largest by enrollment, is one of 3 that started in 2025, is one of 2 in phase 2, and was the 2nd registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →7 of the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–65
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5
First in 2023; this study’s year is marked. 3 started in 2025.
This study's enrollment of 163 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 152 across the 10 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hangzhou Sciwind Biosciences Co., Ltd. is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
4 of the studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07243171Hangzhou Sciwind Biosciences Co., Ltd.A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | 2027-01-05 |
| NCT07073417Hangzhou Sciwind Biosciences Co., Ltd.A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) | 2027-02-27 |
| NCT07936058Hangzhou Sciwind Biosciences Co., Ltd.A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet | 2027-04-15 |
| NCT07929298Hangzhou Sciwind Biosciences Co., Ltd.A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | 2027-09-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity
In this Phase II study, eligible participants will be randomized into one of the two cohorts in a 1:1 ratio to receive once-weekly subcutaneous XW003 injection or semaglutide injection, including a dose-escalation period, a core treatment period and a treatment extension period, for up to 60 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
once weekly
Drug: XW003 injection
once weekly
Drug: semaglutide injection
Subcutaneous injection
Also known as: ecnoglutide
Subcutaneous injection
Percentage change in body weight relative to baseline
Time frame: week 48
Proportions of participants with weight loss ≥5% from baseline
Time frame: week 48
Proportions of participants with weight loss ≥10% from baseline
Time frame: week 48
Proportions of participants with weight loss ≥15% from baseline
Time frame: week 48
The change in waist circumference relative to the baseline
Time frame: week 48
Changes in body mass index (BMI) relative to baseline
Time frame: week 48
Started Jul 2025 (actual). Primary completion is estimated for Feb 2027, 18 months after the start.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 18 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ecnoglutide
Hangzhou Sciwind Biosciences Co., Ltd.